Palacios-Filardo, Jon
Udakis, Matt
Brown, Giles A.
Tehan, Benjamin G.
Congreve, Miles S.
Nathan, Pradeep J.
Brown, Alastair J. H.
Mellor, Jack R. http://orcid.org/0000-0002-7706-8105
Funding for this research was provided by:
Wellcome Trust (101029)
Article History
Received: 16 January 2020
Accepted: 21 July 2021
First Online: 16 September 2021
Change Date: 8 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-27351-z
Competing interests
: G.A.B., B.G.T., M.S.C., P.J.N. and A.J.H.B. are/were employees of Sosei Heptares and are/maybe shareholders of Sosei Group, the parent company of Heptares. Sosei Heptares is a drug discovery and development company working in the field of G-protein-coupled receptor structure-based drug design. J.P.-F., M.U. and J.R.M. declare no competing interests.